Proteostasis Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
February 08 2018 - 7:00AM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage
biopharmaceutical company dedicated to the discovery and
development of groundbreaking therapies to treat cystic fibrosis
(CF) and other diseases caused by dysfunctional protein processing,
today announced that Meenu Chhabra, the Company’s President and
Chief Executive Officer, will present at the LEERINK Partners 7th
Annual Global Healthcare Conference on Thursday, February 15, 2018
at 1:30 p.m. ET at The Lotte New York Palace.
A live audio webcast of the Leerink
Partners presentation will be available on the Event Calendar
page in the Investors & Media section of the Company’s
website, www.proteostasis.com. A replay of the webcast will be
available on the Company’s website following the presentation.
About Proteostasis Therapeutics,
Inc.
Proteostasis Therapeutics, Inc. is a
clinical stage biopharmaceutical company developing small molecule
therapeutics to treat cystic fibrosis (CF) and other diseases
caused by dysfunctional protein processing. Headquartered
in Cambridge, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. In
addition to its multiple programs in cystic
fibrosis, Proteostasis Therapeutics has formed a collaboration
with Astellas Pharma, Inc. to research and identify
therapies targeting the Unfolded Protein Response (UPR)
pathway.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “aim,” “may,” “will,” “expect,”
“anticipate,” “estimate,” “intend,” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation,
statements regarding the expected presentation at an upcoming
conference. Forward-looking statements made in this
release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Such risks and uncertainties
include, without limitation, the possibility final or future
results from our drug candidate trials (including, without
limitation, longer duration studies) do not achieve positive
results or are materially and negatively different from or not
indicative of the preliminary results reported by the Company
(noting that these results are based on a small number of patients
and small data set), uncertainties inherent in the execution and
completion of clinical trials (including, without limitation, the
possibility FDA requires us to run cohorts sequentially
or conduct additional cohorts or pre-clinical or clinical studies),
in the enrollment of CF patients in our clinical trials, in the
timing of availability of trial data, in the results of the
clinical trials, in possible adverse events from our trials, in the
actions of regulatory agencies, in endorsement, if any, by
therapeutic development arms of CF patient advocacy groups, and
those set forth in our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2017 and our
other SEC filings. We assume no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACTS:
Investors:David PittsArgot
Partners212.600.1902david@argotpartners.com
Media:David RosenArgot
Partners212.600.1902david.rosen@argotpartners.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024